|
Name |
Sclarene
|
| Molecular Formula | C20H32 | |
| IUPAC Name* |
(4aS,8S,8aS)-4,4,8a-trimethyl-7-methylidene-8-(3-methylidenepent-4-enyl)-2,3,4a,5,6,8-hexahydro-1H-naphthalene
|
|
| SMILES |
C[C@]12CCCC([C@@H]1CCC(=C)[C@@H]2CCC(=C)C=C)(C)C
|
|
| InChI |
InChI=1S/C20H32/c1-7-15(2)9-11-17-16(3)10-12-18-19(4,5)13-8-14-20(17,18)6/h7,17-18H,1-3,8-14H2,4-6H3/t17-,18-,20+/m0/s1
|
|
| InChIKey |
KYLKKZSVPLUGCC-CMKODMSKSA-N
|
|
| Synonyms |
Sclarene; (+)-sclarene; Iso-biformene; labda-8(17),13(16),14-triene; 511-02-4; Sclaren; 95E3AV9Y7E; Delta(8,17.13,16.14)-labdatriene; (4aS,5S,8aS)-1,1,4a-trimethyl-6-methylene-5-(3-methylenepent-4-en-1-yl)decahydronaphthalene; Naphthalene, decahydro-1,1,4a-trimethyl-6-methylene-5-(3-methylene-4-penten-1-yl)-, (4aS,5S,8aS)-; UNII-95E3AV9Y7E; CHEBI:64281; DTXSID301046577; (4aS,8S,8aS)-4,4,8a-trimethyl-7-methylidene-8-(3-methylidenepent-4-enyl)-2,3,4a,5,6,8-hexahydro-1H-naphthalene
|
|
| CAS | 511-02-4 | |
| PubChem CID | 11323257 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 272.5 | ALogp: | 7.5 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 20 | QED Weighted: | 0.416 |
| Caco-2 Permeability: | -4.564 | MDCK Permeability: | 0.00000941 |
| Pgp-inhibitor: | 0.94 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.127 |
| 30% Bioavailability (F30%): | 0.01 |
| Blood-Brain-Barrier Penetration (BBB): | 0.142 | Plasma Protein Binding (PPB): | 85.50% |
| Volume Distribution (VD): | 2.365 | Fu: | 10.01% |
| CYP1A2-inhibitor: | 0.291 | CYP1A2-substrate: | 0.183 |
| CYP2C19-inhibitor: | 0.271 | CYP2C19-substrate: | 0.844 |
| CYP2C9-inhibitor: | 0.513 | CYP2C9-substrate: | 0.312 |
| CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.774 |
| CYP3A4-inhibitor: | 0.334 | CYP3A4-substrate: | 0.363 |
| Clearance (CL): | 8.347 | Half-life (T1/2): | 0.04 |
| hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.139 |
| Drug-inuced Liver Injury (DILI): | 0.748 | AMES Toxicity: | 0.01 |
| Rat Oral Acute Toxicity: | 0.438 | Maximum Recommended Daily Dose: | 0.886 |
| Skin Sensitization: | 0.904 | Carcinogencity: | 0.759 |
| Eye Corrosion: | 0.824 | Eye Irritation: | 0.844 |
| Respiratory Toxicity: | 0.963 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000956 | ![]() |
0.644 | D04VIS | ![]() |
0.326 | ||
| ENC001844 | ![]() |
0.513 | D0S0NK | ![]() |
0.310 | ||
| ENC002543 | ![]() |
0.462 | D01CKY | ![]() |
0.230 | ||
| ENC003214 | ![]() |
0.459 | D0K5WS | ![]() |
0.222 | ||
| ENC003143 | ![]() |
0.446 | D0H1QY | ![]() |
0.221 | ||
| ENC001070 | ![]() |
0.434 | D02VPX | ![]() |
0.218 | ||
| ENC003102 | ![]() |
0.429 | D07BSQ | ![]() |
0.216 | ||
| ENC000946 | ![]() |
0.418 | D0F1UL | ![]() |
0.216 | ||
| ENC003145 | ![]() |
0.392 | D0T2PL | ![]() |
0.214 | ||
| ENC002923 | ![]() |
0.384 | D08SVH | ![]() |
0.214 | ||